Turn Therapeutics Inc.
TTRX
$3.53
$0.030.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 237.68% | 355.56% | 135.83% | 22.86% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 184.34% | 279.37% | 120.27% | 59.10% | |
| Operating Income | -184.34% | -279.37% | -120.27% | -59.10% | |
| Income Before Tax | -185.74% | -252.49% | -101.46% | -59.66% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -185.74% | -252.49% | -101.46% | -59.66% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -185.74% | -252.49% | -101.46% | -59.66% | |
| EBIT | -184.34% | -279.37% | -120.27% | -59.10% | |
| EBITDA | -187.47% | -288.33% | -123.59% | -59.33% | |
| EPS Basic | -172.40% | -239.10% | -95.92% | -58.23% | |
| Normalized Basic EPS | -172.44% | -239.76% | -95.65% | -59.18% | |
| EPS Diluted | -172.40% | -239.10% | -95.92% | -58.23% | |
| Normalized Diluted EPS | -172.44% | -239.76% | -95.65% | -59.18% | |
| Average Basic Shares Outstanding | 4.99% | 3.73% | 2.67% | 0.57% | |
| Average Diluted Shares Outstanding | 4.99% | 3.73% | 2.67% | 0.57% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |